ReviewCurrent opinion in infectious diseases2010
Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas.
Review in Current opinion in infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- Microbiological quality assessment of fish origin food along the production chain in upper Blue Nile watershed, Ethiopia.Food science & nutrition · 2023Article
- Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.Vaccine · 2019Review
- Human Intestinal Enteroids as a Model System ofInfection and immunity · 2019Article
- Identification of Etiology-Specific Diarrhea Associated With Linear Growth Faltering in Bangladeshi Infants.American journal of epidemiology · 2018Article
- Association between enteropathogens and malnutrition in children aged 6-23 mo in Bangladesh: a case-control study.The American journal of clinical nutrition · 2017Article
- Steps for Shigella Gatekeeper Protein MxiC Function in Hierarchical Type III Secretion Regulation.The Journal of biological chemistry · 2017Article
- Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Human vaccines & immunotherapeutics · 2015Review
- Conventional and molecular investigation of Shigella isolates in relation to an outbreak in the area of Isfahan, Iran.Iranian journal of microbiology · 2013Article
- [Drug therapy of infectious diarrhea: part 1: acute diarrhea].Der Internist · 2013Review
- Genetic characterization of antimicrobial resistance of Shigella flexneri 1c isolates from patients in Egypt and Pakistan.Annals of clinical microbiology and antimicrobials · 2013Article
- Laboratory-based prospective surveillance for community outbreaks of Shigella spp. in Argentina.PLoS neglected tropical diseases · 2013Article
- PulseNet China, a model for future laboratory-based bacterial infectious disease surveillance in China.Frontiers of medicine · 2012Review
- Article
- Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers.EMBO molecular medicine · 2012Article
- Broadly protective Shigella vaccine based on type III secretion apparatus proteins.Infection and immunity · 2012Article
- Molecular diagnosis of diarrhea: current status and future potential.Current infectious disease reports · 2012Article
- Convergent synthesis of the tetrasaccharide repeating unit of the O-antigen of Shigella boydii type 9.Beilstein journal of organic chemistry · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewShigella is the principal cause of clinical dysentery and an important cause of morbidity and mortality among children in impoverished regions. The purpose of this review is to present key findings in the areas of epidemiology, disease control, and treatment of shigellosis. RECENT
findingsRecent research activity has advanced the understanding of the epidemiology and host-pathogen interactions. Increased investment and activity in the area of vaccine development have lead to a diversification of candidates and ongoing technical advances yet continue to yield disappointing results in clinical trials in endemic populations and among the most relevant age groups (children under 2 years of age). The description of the rapid spread of quinolone resistance requires monitoring to ensure appropriate case management, particularly in south-east Asia. The evaluation of adjunctive nutritional therapy in endemic areas has supported the use of green bananas in shortening the duration of Shigella dysentery and persistent diarrhea due to Shigella, as well as improving weight gain in early convalescence. SUMMARY: Despite a great level of activity in basic sciences, there continues to be a large gap in the ability to translate these findings into disease control measures or therapeutic options for individuals living in areas in which shigellosis is endemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.